Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 4/2013

EFFECTS OF BOTULINUM TOXIN-TYPE A IN THE TREATMENT OF CEREBRAL PALSY IN CHILDREN

IULIANA ŞTEFANIA DINU1, HOUSSEIN TOUFIC SEBLANY1*, MONICA SAFER2, DOINA ANCA PLEŞCA2

1.University of Medicine and Pharmacy „Carol Davila”, Dionisie Lupu 37 street, 2nd district, Bucharest
2.Department of Pediatrics and Pediatric Neurology, „Victor Gomoiu” Children Clinical Hospital, University of Medicine and Pharmacy „Carol Davila”, Dionisie Lupu 37 street, 2nd district, Bucharest

Download Full Article PDF

Cerebral palsy (CP) is a chronic disorder of movement and/or posture that presents early (before the age of 2) and continues throughout life. CP is caused by static injury (non-progressive damage to the brain before, during or after birth) to the developing brain. CP is a permanent disease which cannot be cured, but the consequences can be minimized. Spasticity represents a major neuromuscular problem in CP and the children can be hemiplegic, diplegic or quadriplegic. Botulinum toxin (BTX) is one of the most useful antispastic agents used as treatment for spastic CP in children. The aim was to study the effects of BTX on motor function in children with different forms of spastic CP. Spasticity was clinically assessed using Modified Ashworth Scale (MAS). The results showed the efficacy of BTX in diplegia, hemiplegia, quadriplegia.